Kymera Therapeutics Inc (KYMR NASDAQ) stock market data APIs
$88.8351
1.75(2%)
as of December 12, 2025
Try our APIs with
free plan!
Kymera Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Prev. Close
88.8351
Open
90.5891
High
90.6832
Low
86.5245
52 wk Range
19.445-103
Market Cap
7 174 M
Shares Outstanding
79 999 K
Revenue
43 735 K
EPS
-0.94
Beta
2.287
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kymera Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kymera Therapeutics Inc data using free add-ons & libraries
Get Kymera Therapeutics Inc Fundamental Data
Kymera Therapeutics Inc Fundamental data includes:
- Net Revenue: 43 735 K
- EBITDA: -321 535 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
- EPS/Forecast: -0.8613
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kymera Therapeutics Inc News
New
Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock.
A secretive biotechnology-centered hedge fund bought shares of Kymera Therapeutics after the stock soared to its highest level on record. A Form 4 filed with the Securities and Exchange Commission on ...
Kymera's Eczema Drug Gets Fast Track Designation in the United States
Kymera Therapeutics, Inc. KYMR recently announced that the FDA granted Fast Track designation to pipeline candidate KT-621 for the treatment of moderate to severe atopic dermatitis (AD), the most comm...
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Kymera Therapeutics, Inc. WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small ...
Kymera Therapeutics (KYMR) Valuation After KT-621 Fast Track Win and Strong Phase 1b BroADen Trial Data
Kymera Therapeutics (KYMR) just checked two big boxes for biotech investors, pairing strong Phase 1b data for its oral STAT6 degrader KT-621 with an FDA Fast Track nod in atopic dermatitis. See our l...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
